超越双心室节奏:探索心力衰竭中他的捆绑节奏和左捆绑分支节奏的优势 - 一个系统的审查和元分析
Hussam Al Hennawi1, Muhammad Khuzzaim Khan2, Momina Khalid3
1Department of Internal Medicine, Jefferson Abington Hospital, Abington, Philadelphia, USA.
Pacing and clinical electrophysiology : PACE
|December 10, 2023
概括
希斯-普尔金耶系统节奏 (HPSP) 改善了心脏功能和心力衰竭症状,超过了双心室节奏 (BiVP). 一种HPSP的类型LBBP在电同步和缩功能方面表现出优异的结果.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 心脏衰竭管理的管理
背景情况:
- 随着左心室 (LV) 功能障碍和失调的心力衰竭 (HF) 需要先进的节奏治疗.
- 传统的双心脏节奏 (BiVP) 是一种标准的治疗方法,但新的技术正在出现.
研究的目的:
- 在心力衰竭患者中,比较His-Purkinje系统节奏 (HPSP) 与常规双心室节奏 (BiVP) 的疗效.
- 评估HPSP对电同步,心脏功能和临床结果的影响.
- 评估HPSP的不同方式,包括His捆绑分支节奏 (HBP) 和左捆绑分支区域节奏 (LBBP).
主要方法:
- 进行了对18项涉及1291名患者的研究 (5项RCT,13项观察性研究) 的元分析.
- 从多个数据库收集到2023年5月的数据.
- 结果措施包括QRS持续时间,LVEF改善,LVEDD变化,HF住院治疗和NYHA类,使用随机效应模型进行分析.
主要成果:
- 他的捆绑分支节奏 (HBP) 与其他节奏方法相比,导致最短的QRS持续时间.
- 左捆分支区域步调 (LBBP) 在LVEF,LVEDD和NYHA功能类中表现出最显著的改进.
- 在HPSP和BiVP之间没有观察到心力衰竭住院率的显著差异.
结论:
- 作为一个His-Purkinje系统节奏 (HPSP) 技术,LBBP在电心室同步和缩功能方面提供了卓越的结果.
- 与传统节奏相比,HPSP,特别是LBBP在缓解心力衰竭症状方面表现有前途.
- 进一步的研究可能会巩固HPSP在先进的心脏再同步治疗中的作用.
相关概念视频
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:26Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436